What is CG Oncology's D&A?

CG Oncology (CGON) reported D&A of $841K in Q1 2026.

How has CG Oncology's D&A changed year-over-year?

CG Oncology's D&A increased by 3404.2% year-over-year, from $24K to $841K.

What is the long-term trend for CG Oncology's D&A?

Over 2 years (2023 to 2025), CG Oncology's D&A has grown at a 822.0% compound annual growth rate (CAGR), from $17K to $1.45M.

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

CG Oncology CGON D&A

D&A at other companies

PfizerPFE

$1.61B-0.3%

Johnson & JohnsonJNJ

$2B+13.1%

ImmunityBio, Inc.IBRX

$4.38M+14.4%

Cogent Biosciences, Inc.COGT

$626K-2.2%

Tango TherapeuticsTNGX

$463K-25.6%

CelcuityCELC

$47K+27.0%

Other financials

Income statement

See full

Revenue$1.1M+1,983%

Operating income-$66.4M-57.3%

Net income-$60.2M-74.7%

EPS (diluted)-$0.71-57.8%

Balance sheet

See full

Cash & equivalents$33.7M-18.7%

Total debt$7.6M+631%

Total equity$1.1B+54.9%

Total assets$1.1B+55.9%

Cash flow

See full

Operating cash flow-$56.9M-94.5%

CapEx$304.0K+1,800%

Free cash flow-$57.2M-95.4%

Valuation

See full

Market cap$5.39B+206%

Profitability

See full

Operating margin-4,239%-1,872pp

Net margin-3,682.6%-1,601pp

FCF margin-3,163.8%-1,351pp

Returns & leverage

See full

Return on equity-20.8%+7.1pp

Debt / equity0×0.0×

Current ratio31.3×+0.3×

Where this comes from

Reported directly by CG Oncology in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The official record: CG Oncology’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about CG Oncology's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is CG Oncology's D&A?: CG Oncology (CGON) reported D&A of $841K in Q1 2026.
How has CG Oncology's D&A changed year-over-year?: CG Oncology's D&A increased by 3404.2% year-over-year, from $24K to $841K.
What is the long-term trend for CG Oncology's D&A?: Over 2 years (2023 to 2025), CG Oncology's D&A has grown at a 822.0% compound annual growth rate (CAGR), from $17K to $1.45M.
What does D&A mean?: Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.